Clinical and hematologic features of mature T-cell leukemias
. | T-PLL; n = 38 . | Primary SS; n = 32 . | Secondary SS; n = 17 . | T-LGL leukemia; n = 15 . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 63 (41-83) | 61 (37-84) | 62 (30-80) | 53 (24-86) | .26 |
| No. male patients (%) | 19 (50) | 19 (59) | 7 (41) | 10 (67) | .44 |
| No. previously untreated (%) | 19 (50) | 17 (53) | 2 (12) | 11 (73) | .3‡ |
| Median mo of prior symptoms (range) | 2 (0-34) | 24 (0-120) | 38 (0-444) | 9 (1-168) | < .001 |
| Median presenting lymphocyte count, × 109/L (range) | 31.8 (4.7-614.8) | 3.8 (0.2-68.3) | 2.0 (0.5-33.8) | 2.5 (0.35-32.9) | < .001 |
| Median lymphocytes as percentage of total PB WBCs at presentation (range) | 82.5 (43-98) | 40.5 (6-93) | 27.0 (5-86) | 64.0 (52-90) | < .001 |
| Median peak lymphocyte count, × 109/L (range) | 171.3 (20.9-762.0) | 5.9 (0.6-121.9) | 5.7 (1.1-33.9) | 3.6 (0.88-94.1) | < .001 |
| Median lymphocytes as percentage of total PB WBCs at peak (range) | 93 (60-99) | 43 (5-99) | 33 (12-89) | 74 (54-99) | < .001 |
| Median presenting PB neutrophils, × 109/L (range) | 5.2 (0.0-32.7) | 3.8 (0.74-12.0) | 4.3 (0.8-11.1) | 0.65 (0.0-3.5) | < .001 |
| No. with neutropenia at presentation (%)* | 7 (18) | 4 (12) | 2 (12) | 12 (80) | < .001 |
| Median pretreatment PB eosinophils, × 109/L (range) | 0 (0.0-1.1) | 0.81 (0.03-14.6) | 0.7 (0.0-20.6) | 0.14 (0.0-0.9) | < .001 |
| No. with pretreatment PB eosinophilia (%)† | 5 (13) | 21 (66) | 9 (53) | 2 (13) | < .001 |
| No. with palpable lymph nodes at diagnosis (%) | 19 (50) | 20 (63) | 14 (82) | 1 (7) | .0019 |
| No. with hepatosplenomegaly at diagnosis (%) | 25 (66) | 3 (9) | 0 (0) | 8 (53) | < .001 |
| No. with skin findings at diagnosis (%) | 10 (26) | 32 (100) | 17 (100) | 4 (27) | < .001 |
| No. with presence of effusions at diagnosis (%) | 8 (21) | 1 (3) | 0 (0) | 0 (0) | .01 |
| Survival | < .001 | ||||
| No. deaths from disease (%) | 29 (76) | 10 (31) | 10 (59) | 1 (7) | |
| Median OS, mo | 29.5 | NA | 60 | NA | |
| 3-year survival rate, % | 46 | 73 | 64 | 100 |
. | T-PLL; n = 38 . | Primary SS; n = 32 . | Secondary SS; n = 17 . | T-LGL leukemia; n = 15 . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 63 (41-83) | 61 (37-84) | 62 (30-80) | 53 (24-86) | .26 |
| No. male patients (%) | 19 (50) | 19 (59) | 7 (41) | 10 (67) | .44 |
| No. previously untreated (%) | 19 (50) | 17 (53) | 2 (12) | 11 (73) | .3‡ |
| Median mo of prior symptoms (range) | 2 (0-34) | 24 (0-120) | 38 (0-444) | 9 (1-168) | < .001 |
| Median presenting lymphocyte count, × 109/L (range) | 31.8 (4.7-614.8) | 3.8 (0.2-68.3) | 2.0 (0.5-33.8) | 2.5 (0.35-32.9) | < .001 |
| Median lymphocytes as percentage of total PB WBCs at presentation (range) | 82.5 (43-98) | 40.5 (6-93) | 27.0 (5-86) | 64.0 (52-90) | < .001 |
| Median peak lymphocyte count, × 109/L (range) | 171.3 (20.9-762.0) | 5.9 (0.6-121.9) | 5.7 (1.1-33.9) | 3.6 (0.88-94.1) | < .001 |
| Median lymphocytes as percentage of total PB WBCs at peak (range) | 93 (60-99) | 43 (5-99) | 33 (12-89) | 74 (54-99) | < .001 |
| Median presenting PB neutrophils, × 109/L (range) | 5.2 (0.0-32.7) | 3.8 (0.74-12.0) | 4.3 (0.8-11.1) | 0.65 (0.0-3.5) | < .001 |
| No. with neutropenia at presentation (%)* | 7 (18) | 4 (12) | 2 (12) | 12 (80) | < .001 |
| Median pretreatment PB eosinophils, × 109/L (range) | 0 (0.0-1.1) | 0.81 (0.03-14.6) | 0.7 (0.0-20.6) | 0.14 (0.0-0.9) | < .001 |
| No. with pretreatment PB eosinophilia (%)† | 5 (13) | 21 (66) | 9 (53) | 2 (13) | < .001 |
| No. with palpable lymph nodes at diagnosis (%) | 19 (50) | 20 (63) | 14 (82) | 1 (7) | .0019 |
| No. with hepatosplenomegaly at diagnosis (%) | 25 (66) | 3 (9) | 0 (0) | 8 (53) | < .001 |
| No. with skin findings at diagnosis (%) | 10 (26) | 32 (100) | 17 (100) | 4 (27) | < .001 |
| No. with presence of effusions at diagnosis (%) | 8 (21) | 1 (3) | 0 (0) | 0 (0) | .01 |
| Survival | < .001 | ||||
| No. deaths from disease (%) | 29 (76) | 10 (31) | 10 (59) | 1 (7) | |
| Median OS, mo | 29.5 | NA | 60 | NA | |
| 3-year survival rate, % | 46 | 73 | 64 | 100 |
Neutropenia was defined as absolute neutrophil count (ANC) less than 1800 neutrophils/μL peripheral blood.
Eosinophilia was defined as absolute eosinophil count (AEC) greater than 0.5 × 103 eosinophils/μL peripheral blood.
Comparison did not include secondary SS because MF patients were nearly always treated prior to leukemic spread.